Previous 10 | Next 10 |
Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology PR Newswire TORRANCE, Calif. , March 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), ...
Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect Conference PR Newswire TORRANCE, Calif. , Jan. 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment o...
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing Canada NewsWire Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , Dec. 20, 2...
Virtual Conference for Life Sciences Companies Broadcast Live December 16th Canada NewsWire Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , Dec. 14, 2021 /CNW/ - Virtual Investor Co...
Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting Analysis Indicates that Patients Requiring Blood Tr...
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Vi...
Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16th Emmaus invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com PR Newswire ...
Emmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition Emmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Me...
Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...
Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights -- Net Revenues Increased 4% for the Nine Months Ended September 30, 2021 -- PR Newswire TORRANCE, Calif. , Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQ...
News, Short Squeeze, Breakout and More Instantly...
Emmaus Life Sciences Incorporation Company Name:
EMMA Stock Symbol:
NYSE Market:
Emmaus Life Sciences Incorporation Website:
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program PR Newswire TORRANCE, Calif. , July 12, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceuti...
Emmaus Life Sciences Reports 2023 Financial Results PR Newswire TORRANCE, Calif. , July 3, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today r...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...